Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Tempus AI, Inc.

Introducing Tempus One in the EHR with Integrated Guidelines
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus to Present at the William Blair 45th Annual Growth Stock Conference
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Reports First Quarter 2025 Results
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus to Report First Quarter 2025 Financial Results on May 6
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Acquisition of Deep 6 AI
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Reports Fourth Quarter and Full Year 2024 Results
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus to Present at TD Cowen's 45th Annual Health Care Conference
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus to Participate in the Morgan Stanley Technology, Media and Telecom Conference
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Collaboration with IFLI Aimed at Supporting Development of Targeted Therapies for Follicular Lymphoma
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus to Report Fourth Quarter and Full Year 2024 Financial Results on February 24
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Completes Acquisition of Ambry Genetics
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces National Launch of olivia, its AI-enabled Personal Health Concierge App for Patients
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces the National Launch of FDA-Approved xT CDx Test
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Tempus Announces Its First-Ever, Whole-Genome Sequencing Assay, xH
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.